Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
244.29B
Market cap244.29B
Price-Earnings ratio
27.83
Price-Earnings ratio27.83
Dividend yield
2.22%
Dividend yield2.22%
Average volume
2.68M
Average volume2.68M
High today
$465.00
High today$465.00
Low today
$439.70
Low today$439.70
Open price
$442.65
Open price$442.65
Volume
2.91M
Volume2.91M
52 Week high
$465.00
52 Week high$465.00
52 Week low
$288.00
52 Week low$288.00

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $460.00. The company's market cap stands at 244.29B, with a P/E ratio of 27.83 and a dividend yield of 2.22%.

During the trading session on 2026-10-28, Amgen(AMGN) shares reached a daily high of $465.00 and a low of $439.70. At a current price of $460.00, the stock is +4.6% higher than the low and still -1.1% under the high.

Trading volume for Amgen(AMGN) stock has reached 2.91M, versus its average volume of 2.68M.

The stock's 52-week range extends from a low of $288.00 to a high of $465.00.

The stock's 52-week range extends from a low of $288.00 to a high of $465.00.

AMGN News

TipRanks 9h
Amgen says video ad for Vectibix cited by FDA never publicly disseminated - TipRanks

...

Amgen says video ad for Vectibix cited by FDA never publicly disseminated - TipRanks
Zacks 9h
Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?

Amgen (AMGN Quick QuoteAMGN - Free Report) is scheduled to report third-quarter 2026 results on Nov. 3, after market close. In the last reported quarter,...

Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?
Simply Wall St 15h
Amgen Posts Positive Phase 3 Sjögren's Data As Autoimmune Readout Broadens

Amgen (NasdaqGS:AMGN) reported positive Phase 3 OASIZ-301 trial results for dazodalibep in Sjögren's disease, showing reduced disease activity. At ACR Converge...

Analyst ratings

51%

of 37 ratings
Buy
32.4%
Hold
51.4%
Sell
16.2%

More AMGN News

Seeking Alpha 1d
Amgen receives FDA warning letter over Vectibix ad

The US FDA issued Amgen (AMGN) a warning letter over a TV ad for its colorectal cancer treatment Vectibix (panitumumab), with the agency saying that it "creates...

Amgen receives FDA warning letter over Vectibix ad
The Motley Fool 1d
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

The pharmaceutical industry is evolving rapidly, leaving many investors to wonder whether established giants can sustain their momentum. Choosing between Amgen...

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Benzinga 2d
Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer

Amgen Inc. (NASDAQ:AMGN) on Saturday released interim Phase 3 trial results showing that Imdelltra, evaluated in combination with AstraZeneca Plc’s (NYSE:AZN) I...

Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer
The Motley Fool 4d
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?

Stocks in some sectors and industries are known for paying dividends. Consumer staples, energy, and utility stocks are great examples. However, the biotech indu...

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
Bloomberg 4d
Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer - Bloomberg.com

...

Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer - Bloomberg.com
Simply Wall St 4d
Amgen Draws Fresh Valuation Debate After Phase 3 TEZSPIRE Trial Results

Amgen (AMGN) is back in focus after new Phase 3 data for TEZSPIRE in eosinophilic esophagitis, with investors weighing what a broader use case could mean for th...

24/7 Wall St. 5d
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

Investing AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? When a drugmaker's top product loses patent protection, the dividend usually...

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.